Pharmacogenomics Market Research Report: Information By Technology (Microarray, Sequencing, and Polymerase Chain Reaction), By Application (Oncology, Cardiology, and Neurological Disorders), By End User (Hospitals, Research Organizations and Academic Institutes) and By Region (North America, Europe, Asia-Pacific, and Rest of the World) –Market Forecast Till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Pharmacogenomics Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Pharmacogenomics Market: Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Pharmacogenomics Market Size Estimation

Chapter 4. Pharmacogenomics Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Pharmacogenomics Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Pharmacogenomics Market, by Technology

6.1 Introduction

6.2 Microarray

Market Estimates & Forecast, 2020-2025

6.3 Sequencing

Market Estimates & Forecast, 2020-2025

6.3.1 Sanger Sequencing

6.3.2 Pyrosequencing

6.3.3 Next-Generation Sequencing

6.3.4 Others

6.4 Polymerase Chain Reaction

Market Estimates & Forecast, 2020-2025

6.5 Others

Chapter 7. Global Pharmacogenomics Market, by Application

7.1 Introduction

7.2 Oncology

Market Estimates & Forecast, 2020-2025

7.2.1 Breast Cancer

7.2.2 Lung Cancer

7.2.3 Others

7.3 Cardiology

Market Estimates & Forecast, 2020-2025

7.4 Neurological Disorders

Market Estimates & Forecast, 2020-2025

7.5 Others

Market Estimates & Forecast, 2020-2025

Chapter 8 Global Pharmacogenomics Market, by End User

8.1 Introduction

8.2 Hospitals and clinics

Market Estimates & Forecast, 2020-2025

8.3 Research Organizations

Market Estimates & Forecast, 2020-2025

8.4 Academic Institute

Market Estimates & Forecast, 2020-2025

8.5 Others

Market Estimates & Forecast, 2020-2025

Chapter 9. Global Pharmacogenomics Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape: Pharmacogenomics Market

10.1 Introduction

10.2 Pharmacogenomics Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Myriad Genetics, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 23andMe, Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Pathway Genomics

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 GeneTech

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 GeneDx.

11.5.1 Overview

11.5.2 Company Overview

11.5.3 Product Overview

11.5.4 Financial overview

11.5.5 Key Developments

11.6 Future Science Group

11.6.1 Overview

11.6.2 Company Overview

11.6.3 Product Overview

11.6.4 Financial Overview

11.6.5 Key Developments

11.7 Teva Pharmaceutical Industries Ltd.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Assurex Health, Inc.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Pharmacogenomics Industry Synopsis, 2020-2025

Table 2 Global Pharmacogenomics Market Estimates and Forecast, 2020-2025, (USD Million)

Table 3 Global Pharmacogenomics Market by Region, 2020-2025, (USD Million)

Table 4 Global Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 5 Global Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 6 Global Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 7 North America Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 8 North America Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 9 North America Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 10 US Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 11 US Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 12 US Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 13 Canada Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 14 Canada Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 15 Canada Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 16 South America Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 17 South America Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 18 South America Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 19 Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 20 Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 21 Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 22 Western Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 23 Western Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 24 Western Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 25 Eastern Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 26 Eastern Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 27 Eastern Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 28 Asia Pacific Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 29 Asia Pacific Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 30 Asia Pacific Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 31 Middle East & Africa Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 32 Middle East & Africa Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 33 Middle East & Africa Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Pharmacogenomics Market

Figure 3 Segmentation Market Dynamics for Global Pharmacogenomics Market

Figure 4 Global Pharmacogenomics Market Share, by Technology 2020

Figure 5 Global Pharmacogenomics Market Share, by Application 2020

Figure 6 Global Pharmacogenomics Market Share, by End Users, 2020

Figure 7 Global Pharmacogenomics Market Share, by Region, 2020

Figure 8 North America Pharmacogenomics Market Share, by Country, 2020

Figure 9 Europe Pharmacogenomics Market Share, by Country, 2020

Figure 10 Asia Pacific Pharmacogenomics Market Share, by Country, 2020

Figure 11 Middle East & Africa Pharmacogenomics Market Share, by Country, 2020

Figure 12 Global Pharmacogenomics Market: Company Share Analysis, 2020 (%)

Figure 14 Myriad Genetics, Inc.: Key Financials

Figure 15 Myriad Genetics, Inc.: Segmental Revenue

Figure 16 Myriad Genetics, Inc.: Geographical Revenue

Figure 17 23andMe, Inc.: Key Financials

Figure 18 23andMe, Inc.: Segmental Revenue

Figure 19 23andMe, Inc.: Geographical Revenue

Figure 20 Pathway Genomics: Key Financials

Figure 21 Pathway Genomics: Segmental Revenue

Figure 22 Pathway Genomics: Geographical Revenue

Figure 23 GeneTech: Key Financials

Figure 24 GeneTech: Segmental Revenue

Figure 25 GeneTech: Geographical Revenue

Figure 26 GeneDx. : Key Financials

Figure 27 GeneDx. : Segmental Revenue

Figure 28 GeneDx. : Geographical Revenue

Figure 29 Future Science Group: Key Financials

Figure 30 Future Science Group: Segmental Revenue

Figure 31 Future Science Group: Geographical Revenue

Figure 32 Teva Pharmaceutical Industries Ltd.: Key Financial

Figure 33 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 34 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 35 Assurex Health, Inc..: Key Financials

Figure 36 Assurex Health, Inc.: Segmental Revenue

Figure 37 Assurex Health, Inc.: Geographical Revenue